Renal denervation and heart failure

European Journal of Heart Failure

Volumn 16, Issue 6, 2014, Pages 608-613

  Böhm, Michael ^a   Ewen, Sebastian ^a   Kindermann, Ingrid ^a   Linz, Dominik ^a   Ukena, Christian ^a   Mahfoud, Felix ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Heart failure; Hypertension; Renal sympathetic denervation; Sympathetic nervous system

Indexed keywords

MOXONIDINE; NORADRENALIN;

ADVERSE OUTCOME; COMORBIDITY; DIASTOLE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART RATE; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY DISEASE; METABOLIC DISORDER; MULTICENTER STUDY (TOPIC); NORADRENALIN RELEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDERED BREATHING; ADRENERGIC SYSTEM; BLOOD PRESSURE; INNERVATION; KIDNEY; PATHOPHYSIOLOGY; SYMPATHECTOMY; TREATMENT OUTCOME;

BLOOD PRESSURE; HEART FAILURE; HEART RATE; HUMANS; KIDNEY; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84901982262     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.83     Document Type: Review

References (71)

1. Esler M,. The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol 2010; 108: 227-237.
2. Esler M, Lambert G, Jennings G,. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens 1989; A11: 75-89. (Pubitemid 19159111)
3. Grassi G, Facchini A, Trevano FQ, Dell'Oro R, Arenare F, Tana F, Bolla G, Monzani A, Robuschi M, Mancia G,. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005; 46: 321-325. (Pubitemid 41099164)
4. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA,. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003; 108: 3097-3101. (Pubitemid 38031798)
5. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH,. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-1979. (Pubitemid 35176304)
6. Floras JS,. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 2009; 54: 375-385.
7. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T,. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823. (Pubitemid 14035089)
8. Rector TS, Olivari MT, Levine TB, Francis GS, Cohn JN,. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J 1987; 114: 148-152. (Pubitemid 17098554)
9. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S,. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-1729. (Pubitemid 20367975)
10. Swedberg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmley WW, Chatterjee K,. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 1984; 54: 783-786. (Pubitemid 14006148)
11. Goldstein DS, Brush JE Jr, Eisenhofer G, Stull R, Esler M,. In vivo measurement of neuronal uptake of norepinephrine in the human heart. Circulation 1988; 78: 41-48.
12. Böhm M, La Rosée K, Schwinger RH, Erdmann E,. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 1995; 25: 146-153.
13. Böhm M, Gierschik P, Jakobs KH, Pieske B, Schnabel P, Ungerer M, Erdmann E,. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation 1990; 82: 1249-1265.
14. Böhm M, Beuckelmann D, Brown L, Feiler G, Lorenz B, Näbauer M, Kemkes B, Erdmann E,. Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium. Eur Heart J 1988; 9: 844-852.
15. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI,. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73: 615-621. (Pubitemid 16081418)
16. Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B,. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 2005; 26: 906-913. (Pubitemid 40676571)
17. Böhm M, Linz D, Urban D, Mahfoud F, Ukena C,. Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol 2013; 10: 465-476.
18. Sobotka PA, Krum H, Böhm M, Francis DP, Schlaich MP,. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep 2012; 14: 285-292.
19. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP,. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995; 25: 893-897.
20. Norman RA Jr, Murphy WR, Dzielak DJ, Khraibi AA, Carroll RG,. Role of the renal nerves in one-kidney, one clip hypertension in rats. Hypertension 1984; 6: 622-626. (Pubitemid 15210501)
21. O'Hagan KP, Thomas GD, Zambraski EJ,. Renal denervation decreases blood pressure in DOCA-treated miniature swine with established hypertension. Am J Hypertens 1990; 3: 62-64. (Pubitemid 20077356)
22. Page IH,. The effect of renal efficiency of lowering arterial blood pressure in cases of essential hypertension and nephritis. J Clin Invest 1934; 13: 909-915.
23. Page IH, Heuer GJ,. The effect of renal denervation on the level of arterial blood pressure and renal function in essential hypertension. J Clin Invest 1935; 14: 27-30.
24. Smithwick RH, Thompson JE,. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 1953; 152: 1501-1504.
25. Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M,. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 2011; 123: 209-215.
26. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M,. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
27. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917.
28. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M,. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.
29. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA, Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 2012; 126: 2976-2982.
30. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD,. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934.
31. Villarreal D, Freeman RH, Johnson RA, Simmons JC,. Effects of renal denervation on postprandial sodium excretion in experimental heart failure. Am J Physiol 1994; 266: R1599-R1604.
32. Masaki H, Imaizumi T, Harasawa Y, Takeshita A,. Dynamic arterial baroreflex in rabbits with heart failure induced by rapid pacing. Am J Physiol 1994; 267: H92-H99.
33. Clayton SC, Haack KK, Zucker IH,. Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol 2011; 300: F31-F39.
34. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A,; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
35. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, Hoppe UC,. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-909.
36. Schirmer SH, Sayed M, Reil JC, Ukena C, Linz D, Kindermann M, Laufs U, Mahfoud F, Böhm M,. Improvements of left-ventricular hypertrophy and diastolic function following renal denervation-effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol 2014;doi:10.1016/j.jacc.2013.10.073.
37. Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, Hamady M, Hughes AD, Sever PS, Sobotka PA, Francis DP,. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 2013; 162: 189-192.
38. US National Library of Medicine. http://www.ClinicalTrials.gov (online), http://www.clinicaltrials.gov/ct2/show/NCT01639378NCT01639378.2013.
39. Verloop WL, Beeftink MM, Nap A, Bots ML, Velthuis BK, Appelman YE, Cramer MJ, Agema WR, Scholtens AM, Doevendans PA, Allaart CP, Voskuil M,. Renal denervation in heart failure with normal left ventricular ejection fraction. Rationale and design of the DIASTOLE (DenervatIon of the renAl Sympathetic nerves in hearT failure with nOrmal Lv Ejection fraction) trial. Eur J Heart Fail 2013; 15: 1429-1437.
40. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ,. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292: 344-350. (Pubitemid 38944258)
41. Wong CY, Chaudhry SI, Desai MM, Krumholz HM,. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med 2011; 124: 136-143.
42. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A,. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59: 998-1005.
43. Böhm M, Pogue J, Kindermann I, Pöss J, Koon T, Yusuf S,. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. Eur J Heart Fail 2014;doi:10.1002/ejhf.23.
44. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U, Böhm M,. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60: 419-424.
45. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP,. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23: 1250-1257.
46. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M,. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-1946.
47. Witkowski A, Prejbisz A, Florczak E, Ka̧dziela J, Śliwiński P, Bieleń P, Michałowska I, Kabat M, Warchoł E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A,. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-565.
48. Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, Reid J, Van Zwieten PA,. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007; 25: 909-920. (Pubitemid 46573105)
49. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA,. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003; 108: 3097-3101. (Pubitemid 38031798)
50. Parish JM, Somers VK,. Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc 2004; 79: 1036-1046. (Pubitemid 39007025)
51. Linz D, Schotten U, Neuberger HR, Böhm M, Wirth K,. Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. Heart Rhythm 2011; 8: 1436-1443.
52. Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger HR, Wirth K, Böhm M,. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension 2012; 60: 172-178.
53. Linz D, Mahfoud F, Schotten U, Ukena C, Hohl M, Neuberger HR, Wirth K, Böhm M,. Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension 2013; 61: 225-231.
54. Linz D, Hohl M, Nickel A, Mahfoud F, Wagner M, Ewen S, Schotten U, Maack C, Wirth K, Böhm M,. Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. Hypertension 2013; 62: 767-774.
55. Linz D, Wirth K, Ukena C, Mahfoud F, Pöss J, Linz B, Böhm M, Neuberger HR,. Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs. Heart Rhythm 2013; 10: 1525-1530.
56. Ukena C, Bauer A, Mahfoud F, Schreieck J, Neuberger HR, Eick C, Sobotka PA, Gawaz M, Böhm M,. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol 2012; 101: 63-67.
57. Swedberg K, Komajda M, Böhm M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885.
58. Böhm M, Swedberg K, Komajda M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894.
59. Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, Reil J-C, Swedberg K, Tavazzi L,. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102: 11-22.
60. Ukena C, Mahfoud F, Spies A, Kindermann I, Linz D, Cremers B, Laufs U, Neuberger HR, Böhm M,. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol 2013; 167: 2846-2851.
61. Reil J-C, Tardif J-C, Ford I, Lloyd SM, O'Meara E, Komajda M, Borer JS, Tavazzi L, Swedberg K, Böhm M,. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 2013; 62: 1977-1985.
62. f-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J 2012; 33: 1223-1231.
63. f-channel inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J 2012; 34: 2839-2849.
64. Ernsberger PR, Westbrooks KL, Christen MO, et al., A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptors. J Cardiovasc Pharmacol 1992; 20: S1-S10. (Pubitemid 23048800)
65. Swedberg K, Bergh CH, Dickstein K, McNay J, Steinberg M,. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators. J Am Coll Cardiol 2000; 35: 398-404. (Pubitemid 30125531)
66. Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, Wright TJ, Moxonidine Safety and Efficacy (MOXSE) Investigators. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 2002; 105: 1797-1803. (Pubitemid 34408889)
67. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ, MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5: 659-667. (Pubitemid 38043972)
68. Pocock S, Wilhelmsen L, Dickstein K, Francis G, Wittes J,. The data monitoring experience in the MOXCON trial. Eur Heart J 2004; 25: 1974-1978. (Pubitemid 39486015)
69. Doggrell SA,. Moxonidine: some controversy. Expert Opin Pharmacother 2001; 2: 337-350. (Pubitemid 32427735)
70. Coats A,. Heart failure 99-the Moxcon story. Int J Cardiol 1999; 71: 109-111. (Pubitemid 29472378)
71. Wolk R,. Anti-arrhythmic properties of moxonidine-implications for the MOXCON study. Int J Cardiol 2000; 74: 89-92. (Pubitemid 30347508)